Astal Laboratories Ltd Stock Price Today (NSE: ASTALLTD)
Fundamental Score
Astal Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Astal Laboratories Ltd share price today is ₹68.19, down 4.58% on NSE/BSE as of 19 June 2026. Astal Laboratories Ltd (ASTALLTD) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹95.11 (Cr). The 52-week high for ASTALLTD share price is ₹103.20 and the 52-week low is ₹60.45. At a P/E ratio of 9.61x, ASTALLTD is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 30.10% and a debt-to-equity ratio of 0.29.
Astal Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Astal Laboratories Ltd share price chart: 18.75% return over the past month. 52-week high ₹103.20, 52-week low ₹60.45.
Astal Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹73.00 | ₹73.00 | ₹68.00 | ₹68.19 | 18.68K (Cr) | |
| ₹73.50 | ₹76.01 | ₹70.00 | ₹71.46 | 33.96K (Cr) | |
| ₹74.37 | ₹78.37 | ₹71.50 | ₹73.85 | 50.01K (Cr) | |
| ₹73.59 | ₹74.40 | ₹72.72 | ₹74.03 | 10.94K (Cr) | |
| ₹72.90 | ₹74.85 | ₹70.98 | ₹73.23 | 18.08K (Cr) | |
| ₹74.22 | ₹77.89 | ₹70.00 | ₹71.69 | 25.59K (Cr) | |
| ₹76.73 | ₹76.73 | ₹74.00 | ₹74.22 | 11.59K (Cr) | |
| ₹78.90 | ₹79.00 | ₹76.22 | ₹76.73 | 13.33K (Cr) | |
| ₹78.00 | ₹79.49 | ₹78.00 | ₹78.08 | 3.53K (Cr) | |
| ₹80.84 | ₹80.85 | ₹77.26 | ₹78.04 | 31.55K (Cr) |
Astal Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹73.50 | ₹76.01 | ₹68.00 | ₹68.19 | -7.22% | |
| ₹62.00 | ₹91.90 | ₹60.86 | ₹73.85 | +19.11% | |
| ₹72.00 | ₹77.90 | ₹60.45 | ₹62.13 | -13.71% | |
| ₹70.10 | ₹84.00 | ₹64.05 | ₹65.36 | -6.76% | |
| ₹80.20 | ₹84.35 | ₹73.00 | ₹76.60 | -4.49% | |
| ₹88.40 | ₹89.00 | ₹76.99 | ₹79.58 | -9.98% | |
| ₹91.00 | ₹92.60 | ₹80.00 | ₹86.85 | -4.56% | |
| ₹95.55 | ₹99.95 | ₹80.00 | ₹90.69 | -5.09% | |
| ₹83.01 | ₹103.20 | ₹83.00 | ₹95.74 | +15.34% | |
| ₹86.31 | ₹89.00 | ₹80.00 | ₹82.92 | -3.93% | |
| ₹85.00 | ₹96.00 | ₹80.00 | ₹86.48 | +1.74% | |
| ₹80.50 | ₹100.80 | ₹79.55 | ₹87.17 | +8.29% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Astal's revenue growth masks deep profitability and liquidity concerns; microcap illiquidity amplifies the risk.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Recent news primarily consists of regulatory filings regarding closure of trading windows and disclosures related to SEBI regulations.
CORE STORY (THE REAL GAME)
Astal is being priced as a high-growth API player riding the India pharma export wave, with a recent acquisition to vertically integrate. The market is betting on continued high sales growth and margin expansion from the Shree Venus Health Sciences plant acquisition.
- High YoY revenue growth in Q3 FY26
- Acquisition of Shree Venus Health Sciences to expand API capacity
- Promoter buying increases confidence
- Significant order wins in the API segment
- Margin expansion in upcoming quarters
- Further promoter stake increase
- Microcap with low liquidity
- Negative free cash flow of ₹-31.64 Cr
- Declining net profit and margin compression in Q3 FY26
Promoter holding is low at 18.19% and has decreased by 1.74%.
Indian pharma exports are growing, but global pricing pressures remain a headwind.
No major news found after live search.
Profit is NOT converting to cash. Free cash flow 5Y is ₹-31.64 Cr.
The next 3-6 months will be crucial to see if Astal can sustain its revenue growth and improve its margins. Failure to do so will likely lead to a significant correction.
Primary Thesis Risk
Inability to convert revenue growth into sustainable profits and positive cash flow will kill the story.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Astal Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Astal Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ASTALLTD across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (30.10%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (34.78%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (15.05%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 9.61 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (29.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (185.11%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (161.53% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (212.84% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.29)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (12.32x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Negative Free Cash Flow (₹-31.64 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (18.19%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Astal Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Astal Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Astal Laboratories LtdAstal Laborator...Selected✓ ASTALLTD • 512600 | 58/100 | ₹68.19₹68 | ₹95.11₹95.11 | 9.61Average 9.6 Average | 30.10%Excellent 30.10% Excellent | 34.78%Excellent 34.78% Excellent | 0.29Excellent 0.3 Excellent | 212.84%Excellent 212.84% Excellent | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1798.70₹1799 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6556.50₹6557 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4350.40₹4350 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1390.50₹1391 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1292.40₹1292 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2267.50₹2268 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1092.90₹1093 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2320.60₹2321 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1433.70₹1434 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5322.50₹5323 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Astal Laboratories Ltd Quarterly Performance
Latest quarterly metrics for ASTALLTD — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
185.11%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
29.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
212.84%
Compounded annual net profit growth over 5 years
Astal Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ASTALLTD — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Astal Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Astal Laboratories Ltd (ASTALLTD) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Astal Laboratories Ltd
About ASTALLTD (Astal Laboratories Ltd)
Astal Laboratories Ltd is a dynamic pharmaceutical entity rooted in the vibrant city of Jaipur, India. Established in 1993 and recently rebranded in April 2024 from its previous id...entity as Macro International Limited, the company embodies a spirit of reinvention and innovation within the pharmaceutical landscape. ASTALLTD stands as a crucial player in the supply chain, focusing on the meticulous production of pharmaceutical intermediates and bulk drugs, cornerstones for the creation of finished medicinal products. Operating as a subsidiary of Aceso Research Labs LLP, the company benefits from shared expertise and resources, fostering an environment of collaborative research and development. ASTALLTD is poised to meet the growing demand for high-quality pharmaceutical components, contributing to the health and well-being of communities both locally and potentially globally. ASTALLTD's core competency lies in its dedication to manufacturing excellence. The company adheres to stringent quality control measures throughout its production processes, ensuring that its pharmaceutical intermediates and bulk drugs meet rigorous industry standards. This commitment to quality is paramount, reflecting the company's understanding of the critical role these components play in the efficacy and safety of final pharmaceutical products. By focusing on these foundational elements, ASTALLTD empowers other pharmaceutical companies to create effective and reliable medications. The facilities in Jaipur are equipped with advanced technology and staffed by skilled professionals, allowing the company to consistently deliver products that meet the exacting requirements of its diverse clientele. As Astal Laboratories Ltd embarks on this new chapter following its rebranding, it carries forward a legacy of experience combined with a renewed vision for the future. The company is strategically positioned to leverage its existing infrastructure, its skilled workforce, and the collaborative advantages of its association with Aceso Research Labs LLP. With an unwavering focus on quality, innovation, and customer satisfaction, ASTALLTD seeks to expand its presence in the pharmaceutical market, forging lasting partnerships with companies dedicated to improving global health outcomes. The Jaipur headquarters serves as a hub for research, development, and manufacturing, driving ASTALLTD's ambition to become a trusted and reliable supplier of essential pharmaceutical building blocks.
Company Details
Key Leadership
Corporate Events
ASTALLTD Share Price: Frequently Asked Questions
What is the current share price of Astal Laboratories Ltd?
Astal Laboratories Ltd (ASTALLTD) trades at ₹68.19 on NSE and BSE. Market cap ₹95.11 (Cr). Educational data only.
What is the P/E ratio of Astal Laboratories Ltd?
Astal Laboratories Ltd has a P/E of 9.61x vs industry average 31.77x.
What is the Bull Run score for Astal Laboratories Ltd?
Astal Laboratories Ltd has a Bull Run score of 58/100 based on 25+ financial parameters.
Does Astal Laboratories Ltd pay dividends?
Astal Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Astal Laboratories Ltd?
Astal Laboratories Ltd has ROE of 30.10%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Astal Laboratories Ltd?
Astal Laboratories Ltd has debt-to-equity of 0.29.
Is Astal Laboratories Ltd a good investment?
Bull Run gives Astal Laboratories Ltd a score of 58/100. This is not investment advice — consult a SEBI-registered advisor.